11.69
price down icon2.18%   -0.26
 
loading
Schlusskurs vom Vortag:
$11.95
Offen:
$11.84
24-Stunden-Volumen:
1.35M
Relative Volume:
0.55
Marktkapitalisierung:
$828.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-6.2181
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
-2.01%
1M Leistung:
-31.07%
6M Leistung:
+203.64%
1J Leistung:
+32.24%
1-Tages-Spanne:
Value
$11.61
$12.17
1-Wochen-Bereich:
Value
$11.45
$12.68
52-Wochen-Spanne:
Value
$2.95
$17.65

Omeros Corporation Stock (OMER) Company Profile

Name
Firmenname
Omeros Corporation
Name
Telefon
206-676-5000
Name
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Name
Mitarbeiter
202
Name
Twitter
@OmerosCorp
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
OMER's Discussions on Twitter

Vergleichen Sie OMER mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
OMER
Omeros Corporation
11.69 847.26M 0 -117.81M 74.30M -1.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.90 120.69B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.45 78.77B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
840.50 52.46B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
338.06 45.82B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.38 38.73B 4.98B 69.59M 525.67M 0.5197

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-10 Eingeleitet H.C. Wainwright Buy
2024-12-23 Eingeleitet D. Boral Capital Buy
2024-11-14 Eingeleitet Rodman & Renshaw Buy
2022-12-08 Herabstufung UBS Buy → Neutral
2022-11-08 Herabstufung BofA Securities Neutral → Underperform
2022-06-08 Herabstufung BofA Securities Buy → Neutral
2021-10-08 Herabstufung JP Morgan Neutral → Underweight
2021-10-01 Herabstufung Maxim Group Buy → Hold
2021-10-01 Herabstufung Wedbush Neutral → Underperform
2021-09-27 Eingeleitet JP Morgan Neutral
2021-02-01 Eingeleitet UBS Buy
2020-10-20 Eingeleitet BofA Securities Buy
2020-08-21 Bestätigt H.C. Wainwright Buy
2020-08-14 Bestätigt Maxim Group Buy
2019-05-06 Eingeleitet Cantor Fitzgerald Overweight
2018-07-12 Eingeleitet Seaport Global Securities Buy
2018-03-23 Herabstufung Wedbush Outperform → Neutral
2018-03-05 Herabstufung Needham Buy → Hold
2017-11-08 Eingeleitet H.C. Wainwright Buy
2017-05-11 Herabstufung Cantor Fitzgerald Buy → Neutral
2017-03-17 Bestätigt Maxim Group Buy
2017-03-17 Bestätigt Needham Buy
2016-11-16 Bestätigt Wedbush Outperform
2016-11-10 Bestätigt Needham Buy
2016-08-10 Bestätigt Maxim Group Buy
2016-06-03 Eingeleitet Cantor Fitzgerald Buy
2016-03-02 Bestätigt Needham Buy
2016-02-29 Bestätigt Wedbush Outperform
2015-11-11 Bestätigt Needham Buy
2015-08-18 Bestätigt WBB Securities Strong Buy
2015-08-10 Eingeleitet ROTH Capital Buy
Alle ansehen

Omeros Corporation Aktie (OMER) Neueste Nachrichten

pulisher
Jan 29, 2026

Is Omeros Corporation gaining market shareJuly 2025 Gainers & Safe Entry Momentum Stock Tips - mfd.ru

Jan 29, 2026
pulisher
Jan 28, 2026

Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia

Jan 28, 2026
pulisher
Jan 27, 2026

Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha

Jan 27, 2026
pulisher
Jan 27, 2026

OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com South Africa

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros announces first commercial sales of Yartemlea - TipRanks

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance

Jan 27, 2026
pulisher
Jan 27, 2026

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Jan 27, 2026
pulisher
Jan 26, 2026

A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com

Jan 26, 2026
pulisher
Jan 24, 2026

Omeros wins FDA nod for transplant therapy - MSN

Jan 24, 2026
pulisher
Jan 23, 2026

Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat

Jan 23, 2026
pulisher
Jan 20, 2026

Portfolio Update: Can Omeros Corporation maintain sales growthJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Jan 20, 2026
pulisher
Jan 19, 2026

Growth Value: Should you buy the dip on Omeros CorporationQuarterly Growth Report & Fast Gain Stock Tips - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 16, 2026

Omeros Shares Face Headwinds Amid Mixed Signals - AD HOC NEWS

Jan 16, 2026
pulisher
Jan 16, 2026

Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN

Jan 16, 2026
pulisher
Jan 15, 2026

Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares - MarketBeat

Jan 14, 2026
pulisher
Jan 14, 2026

Omeros (OMER) Price Target Increased by 29.70% to 44.54 - Nasdaq

Jan 14, 2026
pulisher
Jan 14, 2026

Omeros VP Borges sells $750k in shares By Investing.com - Investing.com Nigeria

Jan 14, 2026
pulisher
Jan 14, 2026

Omeros VP Borges sells $750k in shares - Investing.com

Jan 14, 2026
pulisher
Jan 13, 2026

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - msn.com

Jan 13, 2026
pulisher
Jan 12, 2026

HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings - MarketBeat

Jan 12, 2026
pulisher
Jan 11, 2026

Why did Omeros stock jump 5% in after-hours trading today? - MSN

Jan 11, 2026
pulisher
Jan 10, 2026

Omeros (OMER) Price Target Increased by 12.22% to 34.34 - MSN

Jan 10, 2026
pulisher
Jan 10, 2026

Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN

Jan 10, 2026
pulisher
Jan 10, 2026

Will Omeros Corporation stock see insider buyingRecovery Day Options & size guide reminders to avoid returns - Улправда

Jan 10, 2026
pulisher
Jan 10, 2026

Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - MarketBeat

Jan 10, 2026
pulisher
Jan 09, 2026

Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus - MarketBeat

Jan 09, 2026
pulisher
Jan 09, 2026

What is HC Wainwright's Forecast for Omeros Q1 Earnings? - MarketBeat

Jan 09, 2026
pulisher
Jan 08, 2026

Fundamentals Check: Will Omeros Corporation stock see insider buyingMarket Growth Report & Daily Stock Momentum Reports - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Why Omeros Corporation stock could benefit from AI revolutionJuly 2025 Technicals & Growth-Oriented Investment Plans - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Why retail investors pile into Omeros Corporation stock2025 Sector Review & Technical Entry and Exit Tips - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade - MarketBeat

Jan 08, 2026
pulisher
Jan 08, 2026

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²

Jan 08, 2026
pulisher
Jan 08, 2026

OMER: HC Wainwright & Co. Raises Price Target to $40 with Buy Ra - GuruFocus

Jan 08, 2026
pulisher
Jan 08, 2026

OMER's Rating Maintained as 'Buy' with $36 Price Target by Analyst | OMER Stock News - GuruFocus

Jan 08, 2026
pulisher
Jan 08, 2026

Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros - TipRanks

Jan 08, 2026
pulisher
Jan 08, 2026

Omeros (NASDAQ:OMER) Price Target Raised to $40.00 - MarketBeat

Jan 08, 2026

Finanzdaten der Omeros Corporation-Aktie (OMER)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$96.95
price down icon 1.27%
$100.07
price down icon 1.00%
$32.63
price down icon 2.16%
$113.75
price down icon 2.59%
$156.87
price down icon 0.60%
biotechnology ONC
$340.38
price down icon 2.75%
Kapitalisierung:     |  Volumen (24h):